BACKGROUND: Despite the high morbidity and mortality of heart failure with preserved ejection fraction (HFpEF), treatment ...

Medera Inc. (“Medera”), a clinical-stage biopharmaceutical company focused on targeting difficult-to-treat and currently ...

Dropsy, described in the 17th century, treated with “cure de dechloruration” (bloodletting, leeching, and lancing) and a ...

AI-assisted diagnosis of asymptomatic left ventricular dysfunction may detect disease early and thereby expedite treatment of ...

In seven patients with Danon disease, a single infusion of adeno-associated virus serotype 9 carrying transgene LAMP2B ...

UK: A secondary analysis of the FINEARTS-HF randomized clinical trial evaluated the performance of the PREDICT-HFpEF model in ...

Does finerenone improve outcomes in patients withheart failure (HF) with mildly reduced or preserved ejection fraction?

Medera announced that patient dosing has been completed in its MUSIC-HFrEF Phase 1/2a clinical trial of the gene therapy candidate SRD-001 in ...

The following is a summary of "Tissue-tracking mitral annular displacement predicts impaired left ventricular mechanics and ...